UnknownNot Applicable

The Therapeutic Evaluation(Both Short-term and Long-term Outcome) of Minimal Invasive Radical Antegrade Modular Pancreatosplenectomy for Left-sided Pancreatic Cancer Patients

China125 participantsStarted 2020-07-01

Plain-language summary

Pancreatic cancer is regarded as "the king of cancer". It is extremely malignant, with a low sensibility to chemotherapy and radiotherapy, and a poor prognosis. Surgical treatment is very important for pancreatic cancer. Radical antegrade modular pancreatosplenectomy (RAMPS) is a standard method for treating pancreatic cancer at the body and tail of pancreas. In the same surgical approach, the investigators are going to compare and discuss the advantages of laparoscopic and open RAMPS in the RCT study.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. 18 years old and older;
✓. Pathology diagnosed as pancreatic adenocarcinoma or suspect cancer mass at the pancreatic body or tail;
✓. Patients who are eligible and planned to be performed RAMPS procedure;
✓. Resectable or borderline resectable tumor by preoperative evaluation.

Exclusion criteria

✕. Patients with evidence of distant metastasis or advanced arterial invasion so that are not able to continue radical surgery;
✕. ASA≥4；
✕. Patients who are not willing to be performed open and/or mi-RAMPS;
✕. Not pancreatic adenocarcinoma by posteroperative pathology.

What they're measuring

Posteroperative length of stay

Timeframe: Until patients were discharged

Trial details

NCT IDNCT03770559

SponsorPeking Union Medical College Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-06-30

Contact for this trial

HANYU ZHANG, M.D.

01069152600 medzhy5813@126.com

View on ClinicalTrials.gov More Pancreatic Cancer trials